Firstly, although anti-PD-1/PD-L1 therapies exhibit potent antitumor effects, only patients with certain cancer subtypes can benefit from anti-PD-1/PD-L1 immunotherapy, such as NSCLC 159, TNBC [160]and melanoma 161. Here, PDCD1 is linked to non-small cell lung carcinoma.